Cerveau Technologies, Inc, which is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group to globally develop diagnostics and technology that positively impacts patients with neurodegenerative disorders, has announced an agreement with Massachusetts General Hospital (MGH) to support multiple projects over the next several years.
The projects surround an early stage imaging agent called MK-6240 to be used in positron emission tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.
Cerveau will contract with research center and PET imaging facility within MGH the Gordon Center for Medical Imaging to manufacture and supply the agent for initiatives in the greater Boston area.
“The value of this novel technology has already been demonstrated to improve the likelihood we can develop treatments for Alzheimer’s disease,” said Dr Keith Johnson, Leader of the Aging NeuroImaging Program at the MGH Gordon Center, and the Harvard Aging Brain Study. “Cerveau welcomes this opportunity to work with the MGH researchers, who have a very successful history of leadership in this field to understand the application of MK-6240 and how it may benefit patients with brain diseases.”